March 5 (Reuters) - The U.S. Food and Drug
Administration approved the expanded use of ARS Pharmaceuticals' ( SPRY )
nasal spray for severe allergic reactions in patients
who weigh between 15 to 30 kilograms, the company said on
Wednesday.